Compare Manulife Financial Corporation (MFC) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manulife Financial Corporation vs Neurocrine Biosciences Inc — how do they compare? Manulife Financial Corporation trades at $43.84 (market cap $73.19B), while Neurocrine Biosciences Inc trades at $162.07 (market cap $16.76B). The key difference: Manulife Financial Corporation is far larger — about 4.4× Neurocrine Biosciences Inc's market cap, and Manulife Financial Corporation pays a 3.08% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| MFC | NBIX | |
|---|---|---|
Market Cap | $73.19B | $16.76B |
Sector | Financials | Health |
52-Week High | $44.77 | $185.50 |
52-Week Low | $29.90 | $123.10 |
Enterprise Value | $68.35B | $16.78B |
Dividend Yield | 3.08% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Manulife Financial (MFC) trades at $44.32, down 0.58% with a bullish technical outlook supported by moving averages. The company reported strong Q2 2026 results with double-digit growth in Asia and insurance sales, beating EPS expectations. Revenue reached $53.01B in 2025 with net income of $5.78B, though profit margins have moderated from 2022 peaks. Analysts maintain a Moderate Buy consensus with 57% buy ratings.
MFC presents a positive investment case with solid earnings growth, expanding Asian operations, and consistent dividend payments. However, premium valuation metrics and moderating profit margins warrant caution. The stock faces risks from wealth management outflows and competitive pressures in core markets, requiring careful monitoring of Q3 earnings performance.
Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.
The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Manulife Financial Corporation
Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
